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Management	of	obstructive	nephropathy	 in	a	 tertiary	hospital	 in	North	West	Nigeria:	A	
five-year	review	

















prostatic	 hyperplasia	 (BPH,	 22.6%),	 bilateral	 ureteric	 stone	 (5.7%)	 and	 bilateral	
schistosomal	 lower	 ureteric	 obstruction	 (4.7%).	 Urethral	 or	 suprapubic	 catheterisation	
(22.6%),	 nephrostomy	 (2.8%)	 and	 dialysis	 (10.4%)	 were	 the	 initial	 treatments.	
Chemoradiation	was	done	for	the	patients	with	bladder	cancer	and	17.9%	of	the	patients	
had	operative	interventions,	which	included	ureteroneocystostomy,	open	prostatectomy	or	
transurethral	 resection	of	 the	prostate,	and	ureteroscopy	+	 lithotripsy.	 Fifty-two	patients	
(49.1%)	died	while	awaiting	dialysis	and	 four	patients	(3.8%)	developed	end-stage	renal	
disease.	
Conclusions:	Bladder	carcinomas,	BPH,	ureteric	obstruction	are	 the	 commonest	 causes	of	






suprapubic	 or	 urethral	 catheterisation	 for	 continuous	 bladder	 drainage	 or	 dialysis	 before	
definitive	treatment,	depending	on	the	level	and	degree	of	obstruction.1,2	It	can	progress	to	end-
stage	 renal	 disease	 (ESRD)	 which	 can	 be	 cured	 only	 by	 renal	 transplantation.	 Obstructive	
uropathy	 is	 the	 third	 commonest	 cause	 of	 ESRD	 in	 Sokoto,3	 and	 accounts	 for	 7%	 of	 ESRD	 in	
Ibadan,4	 10%	 of	 acute	 renal	 failure	 and	 four	 percent	 of	 ESRD	 in	 America.5	 This	 study	 was	














recruited	 for	 the	 study.	 Exclusion	 criteria	 included	 incomplete	 records	 and	 coexisting	
nonobstructive	 nephropathy	 such	 as	 human	 immunodeficiency	 virus-associated	 nephropathy	
(HIVAN)	as	evidenced	by	absence	of	hydronephrosis.		
Biochemical	 indications	 for	 dialysis	 were	 serum	 urea	 ≥	 30	 mmol/L,	 creatinine	 ˃11	 mg%,	
bicarbonate	˂10	mmol/L	and	hyperkalaemia	˃6.5	mmol/l.	Clinical	indications	for	dialysis	were	
presence	 of	 signs	 and	 symptoms	 of	 uraemia	 such	 as	 gastrointestinal	 bleeding,	 pericarditis,	
pulmonary	 oedema	 and	 encephalopathy.	 Acute	 presentation	 is	 defined	 as	 sudden	 onset	 of	
azotaemia	within	hours	and	days	in	apparently	normal	individual	following	urinary	tract	injuries.	






Table 1: Modes of presentation of patients with obstructive nephropathy 
Presenting signs, symptoms, or syndrome n % 
Lower urinary tract symptoms 92 86.8 
Haematuria 69 65.1 
Urinary tract infection 21 19.8 
Colicky flank pain 12 11.7 
Hypertension 10 9.4 
Chronic urinary retention 8 7.5 
Acute urinary retention 8 7.5 
Pyonephrosis 5 4.7 
Urinary incontinence  2 1.9 
Anuria 1 0.9 
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pain	 (11.3%).	 Other	 details	 of	 the	 presentation	 are	 shown	 in	 Table	 1.	 All	 the	 patients	 had	
azotaemia	and	proteinuria	of	at	least	2+.	
The	most	common	causes	of	obstructive	nephropathy	were	bladder	carcinoma	(49.1%),	benign	
prostatic	 hyperplasia	 (BPH)	 (22.6%),	 ureteric	 stone	 (5.8%),	 and	 schistosomal	 bilateral	 lower	
ureteric	 obstruction	(4.8%).	Other	 causes	are	shown	 in	Table	2.	 Patients	with	bladder	 cancer	




Initially	 ureteric	 stones	were	managed	with	 ureterolithotomy	 but	with	 the	 availability	 of	 the	




Table 2: Causes of obstructive nephropathy  
Cause n % 
Bladder carcinoma 52 49.1 
Benign prostatic hyperplasia 24 22.6 
Urolithiasis 9 8.5 
 Bilateral renal 1 0.9 
 Unilateral staghorn calculus + PUJO 1 0.9 
 Bilateral ureteric 6 5.8 
 Bladder 1 0.9 
Bilateral ureteric obstruction 8 7.5 
 Vesical schistosomiasis 5 4.8 
 Post-hysterectomy ureteric ligation 1 0.9 
 Recurrent VVF + ureteric obstruction 1 0.9 
 Retroperitoneal tumour 1 0.9 
Urethral stricture 4 3.7 
Urethral stenosis 1 0.9 
Carcinoma of the prostate 4 3.7 
Intraperitoneal bladder rupture 2 1.9 
Posterior urethral valve 2 1.9 
Total 106 100.0 
PUJO =  pelvi-ureteric junction obstruction; VVF = vesico–vaginal fistula 
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Table 3: Management of obstructive nephropathy 
Treatment modality n % 
Urinary diversion 27 25.4 
Catheterisation 24 22.6 
 Urethral  17 16.0 
 Suprapubic   6.6 
Nephrostomy (unilateral)  3 2.8 
Dialysis (indicated)  60 56.6 
 Haemodialysis  10 9.4 
 Peritoneal dialysis  1 1.0 
Conservative 
 19 18.0 
Total 106 100 
	
Table 4: Operative interventions for obstructive nephropathy 
Procedure  n % 
Open  13 12.2 
 Ureteroneocystostomy 3 2.9 
 Ureterolithotomy 2 1.8 
 Bladder repair + catheterisation 2 1.9 
 Urethroplasty 2 1.9 
 Open simple prostatectomy 1 0.9 
 Bilateral total orchidectomy 1 0.9 
 Pyeloplasty + pyelolithotomy 1 0.9 
 Nephrectomy + stone removal 1 0.9 
Endoscopic 6 5.7 
 Bilateral ureteroscopy + lithotripsy 2 1.9 
 TURP 2 1.9 
 PUV ablation 1 0.9 
 Urethroscopy + dilatation + catheterisation 1 0.9 
Not done 87 82.1 
Total 106 100.0 
TURP = transurethral resection of the prostate; PUV = posterior urethral valve 
There	 was	 full	 recovery	 of	 renal	 function	 in	 the	 19	 patients	 (17.9%)	 who	 had	 operative	
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renal	 damage	 due	 to	 urinary	 tract	 obstruction.8	 Obstructive	 nephropathy	 presents	 with	






quality	 of	 life,	 and	well-resourced	 healthcare	 systems	 in	 the	Western	 countries.	 There	was	 a	
higher	male-to-female	ratio	in	our	study	than	in	the	other	studies.8,10	The	difference	in	male-to-
female	 ratio	 in	 this	 series	may	 be	 due	 to	 higher	 prevalence	 of	 urinary	 schistosomiasis	 from	
greater	exposure	of	men	to	the	parasites	during	farming	and	fishing	activities.	
Only	3.8%	of	patients	in	our	study	had	acute	presentation	compared	to	34%	reported	in	Sudan12;	
this	might	 be	 related	 to	 the	much	 larger	 sample	 size	 of	 the	multicentre	 study	 in	 Sudan.	 The	
commonest	presentations	in	our	patients	were	lower	urinary	tract	symptoms,	haematuria,	flank	





commonest	 causes.2,10,11	 This	 is	 due	 to	 the	 fact	 that	 bladder	 cancer	 is	 the	 commonest	 male	
malignancy	in	Sokoto,	Nigeria	as	a	consequence	of	high	prevalence	of	urinary	schistosomiasis.13	
Other	causes	also	noted	in	our	study	were	urethral	strictures,	prostate	cancer,	posterior	urethral	





renal	 impairment	 had	 urinary	 diversion	 or	 dialysis	 before	 definitive	 treatment.14	 Emergency	
dialysis	was	required	in	57%	of	our	patients,	which	was	higher	than	23%	and	41%	reported	by	
previous	 studies.10,12	 In	 contrast	 to	 the	 other	 studies,	 only	 ten	 percent	 of	 the	 patients	 could	
commence	the	dialysis	due	financial	constraint,	other	patients	died	or	left	against	medical	advice	
before	the	dialysis.	Even	those	that	commenced	the	dialysis	were	unable	to	maintain	it	after	the	
third	 session	or	undergo	 transplantation.	This	was	observed	 in	previous	 studies.3,4	Also,	 only	
about	 28%	 of	 our	 patients	 were	 offered	 definitive	 operative	 interventions	 and	 palliative	




histological	 subtype	 of	 bladder	 cancer	 in	 Sokoto	 is	 squamous	 cell	 type,14	 and	 does	 not	
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Four	 patients	 developed	 end-stage	 renal	 disease	 (ESRD)	 in	 our	 series	 and	 none	 had	 renal	
transplantation.	This	was	contrary	to	the	previous	studies	where	two	and	four	patients	developed	






There	 is	a	need	 to	subsidise	dialysis	and	renal	 transplantation	by	government	 through	health	
insurance.	 The	 current	 National	 Health	 Insurance	 Scheme	 (NHIS)	 can	 be	 upgraded	 to	 offer	
unlimited	cover	 for	dialysis	and	renal	transplantation	services	 to	 those	 individuals	within	the	





Bladder	 carcinoma,	 BPH,	 bilateral	 ureteric	 stones,	 and	 schistosomal	 bilateral	 lower	 ureteric	
obstruction	 are	 the	 commonest	 causes	 of	 obstructive	 nephropathy	 in	 our	 practice.	 Urinary	
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